Pharmacokinetics of paclitaxel-containing liposomes in rats
Journal Title: The AAPS Journal - Year 2003, Vol 5, Issue 4
Abstract
In animal models, liposomal formulations of paclitaxel possess lower toxicity and equal antitumor efficacy compared with the clinical formulation, Taxol. The goal of this study was to determine the formulation dependence of paclitaxel pharmacokinetics in rats, in order to test the hypothesis that altered biodistribution of paclitaxel modifies the exposure of critical normal tissues. Paclitaxel was administered intravenously in either multilamellar (MLV) liposomes composed of phosphatidylglycerol/phosphatidylcholine (L-pac) or in the Cremophor EL/ethanol vehicle used for the Taxol formulation (Cre-pac). The dose was 40 mg/kg, and the infusion time was 8 to 9 minutes. Animals were killed at various times, and pharmacokinetic parameters were determined from the blood and tissue distribution of paclitaxel. The area under the concentration vs time curve (AUC) for blood was similar for the 2 formulations (L-pac: 38.1±3.32 μg-h/mL; Cre-pac: 34.5±0.994 μg-h/mL), however, the AUC for various tissues was formulation-dependent. For bone marrow, skin, kidney, brain, adipose, and muscle tissue, the AUC was statistically higher for Cre-pac. For spleen, a tissue of the reticuloendothelial system that is important in the clearance of liposomes, the AUC was statistically higher for L-pac. Apparent tissue partition coefficients (Kp) also were calculated. For bone marrow, a tissue in which paclitaxel exerts significant toxicity, Kp was 5-fold greater for paclitaxel in Cre-pac. The data are consistent with paclitaxel release from circulating liposomes, but with efflux delayed sufficiently to retain drug to a greater extent in the central (blood) compartment and reduce penetration into peripheral tissues. These effects may contribute to the reduced toxicity of liposomal formulations of paclitaxel.
Authors and Affiliations
Gerald J. Fetterly, Robert M. Straubinger
Keywords
Related Articles
- EP ID EP681989
- DOI 10.1208/ps050432
- Views 103
- Downloads 0
Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration
The subcutaneous (SC) route is of growing interest for the administration of biotherapeutics. Key products on the biotherapeutic market such as insulins, but also several immunoglobulins or Fc-fusion proteins, are admini...
Simultaneous Pharmacokinetic Model for Rolofylline and both M1-trans and M1-cis Metabolites
The online version of this article (doi:10.1208/s12248-012-9443-5) contains supplementary material, which is available to authorized users.
Protective Effects of Kaempferol on Isoniazid- and Rifampicin-Induced Hepatotoxicity
The online version of this article (doi:10.1208/s12248-013-9490-6) contains supplementary material, which is available to authorized users.
CDER Risk Assessment Exercise to Evaluate Potential Risks from the Use of Nanomaterials in Drug Products
The Nanotechnology Risk Assessment Working Group in the Center for Drug Evaluation and Research (CDER) within the United States Food and Drug Administration was established to assess the possible impact of nanotechnology...
Cannabinoids, electrophysiology, and retrograde messengers: Challenges for the next 5 years
Most of the behavioral effects of cannabis and its active ingredients, the cannabinoids (Δ9THC being the most abundant of these), appear to be mediated by cannabinoid receptors. Endogenous cannabinoids (endocanna...